Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Ho Peter Tai-Ching Create: Alert

All | News | Filings
Date FiledTypeDescription
10/27/2022 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
10/26/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/26/2022 4 Ho Peter Tai-Ching (Director) has filed a Form 4 on Aravive, Inc.
Txns: Granted 97,063 options to buy @ $0.9152, valued at $88.8k
09/13/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/02/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/21/2021 3 Form 3 - Initial statement of beneficial ownership of securities:
10/25/2017 4 Ho Peter Tai-Ching (Chief Development Officer) has filed a Form 4 on Epizyme, Inc.
Txns: Sold 15,000 shares @ $16.4394, valued at $246.6k
Exercised 15,000 options to buy @ $8.98, valued at $134.7k
09/26/2017 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/28/2017 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/26/2017 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/27/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
05/26/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
03/02/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
02/09/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
12/12/2016 4 Form 4 - Statement of changes in beneficial ownership of securities
09/01/2016 4 Ho Peter Tai-Ching (Chief Development Officer) has filed a Form 4 on Epizyme, Inc.
Txns: Granted 1,362 shares @ $6.2135, valued at $8.5k
03/31/2016 4/A Ho Peter Tai-Ching (Chief Development Officer) has filed a Form 4 on Epizyme, Inc.
Txns: Bought 2,000 shares @ $16.51, valued at $33k
03/02/2016 4 Form 4 - Statement of changes in beneficial ownership of securities

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy